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Abstract In contrast to extracellular plaque and intra-
cellular tangle pathology, the presence and relevance of
intraneuronal Ab in Alzheimer’s disease (AD) is still a
matter of debate. Human brain tissue offers technical
challenges such as post-mortem delay and uneven or
prolonged tissue ﬁxation that might affect immunohisto-
chemical staining. In addition, previous studies on
intracellular Ab accumulation in human brain often used
antibodies targeting the C-terminus of Ab and differed
strongly in the pretreatments used. To overcome these
inconsistencies, we performed extensive parametrical
testing using a highly speciﬁc N-terminal Ab antibody
detecting the aspartate at position 1, before developing an
optimal staining protocol for intraneuronal Ab detection in
parafﬁn-embedded sections from AD patients. To rule
out that this antibody also detects the b-cleaved APP
C-terminal fragment (b-CTF, C99) bearing the same epi-
tope, parafﬁn-sections of transgenic mice overexpressing
the C99-fragment were stained without any evidence for
cross-reactivity in our staining protocol. The staining
intensity of intraneuronal Ab in cortex and hippocampal
tissue of 10 controls and 20 sporadic AD cases was then
correlated to patient data including sex, Braak stage, plaque
load, and apolipoprotein E (ApoE) genotype. In particular,
the presence of one or two ApoE4 alleles strongly corre-
lated with an increased accumulation of intraneuronal Ab
peptides. Given that ApoE4 is a major genetic risk factor
for AD and is involved in neuronal cholesterol transport, it
is tempting to speculate that perturbed intracellular traf-
ﬁcking is involved in the increased intraneuronal Ab
aggregation in AD.
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Introduction
Genetic studies on familial Alzheimer’s disease (AD)
patients have revealed mutations in genes linked to the beta
amyloid (Ab) generating cascade. Although this provides
strong support for the amyloid hypothesis as the underlying
pathological mechanism of AD [30], some controversies
remain to be resolved. For instance, the accumulation of
extracellular Ab plaques does not correlate with the cog-
nitive decline observed in AD patients [1]. In addition, a
massive loss of neurons around plaques is not seen in
human brain [54] and only rarely observed after the onset
of Ab plaque pathology in various different mouse models
[22, 24].
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lular Ab plaque deposition, accumulation of Ab inside
neurons could be driving AD pathology, and may eventu-
ally lead to intracellular deﬁcits in function and neuronal
loss [25, 37, 68]. Intraneuronal Ab has been reported to
disrupt fast axonal transport (FAT) in isolated axoplasms
[50], to impair multi vesicular body (MVB) sorting by
inhibition of the ubiquitin–proteasome system [2] and to
induce synaptic dysfunction leading to reduced PSD-95
and consequently GluR1 levels in synapses [3].
The accumulation of intraneuronal Ab peptides in AD
brain has been sporadically reported since the late 1980s
[27]. However, initial problems with the inability of the
antibodies to separate between full length amyloid pre-
cursor protein (APP) and Ab itself founded a skepticism
toward the presence of intraneuronal Ab that has been
difﬁcult to eliminate [25, 37]. Despite the initial technical
complications, several studies using Ab40/42 end-speciﬁc
antibodies have later reported the presence of intraneuronal
Ab in AD and healthy controls [17–19, 23, 26, 44, 46, 65],
as well as in Down syndrome patients who are known to
develop AD at an early age [29, 45]. One study isolated
human hippocampal pyramidal neurons from the CA1 of
AD patients by laser capture microdissection, determined
Ab peptide levels using ELISA quantiﬁcation and reported
an increased intraneuronal Ab42/Ab40 ratio in AD patients
compared to controls [4]. Still, the presence and impact of
intraneuronal Ab in human AD tissue is a matter of con-
troversial debate [22].
The data on intraneuronal Ab in AD mouse models are
quite consistent; intraneuronal Ab was ﬁrst reported in
familial PS1 transgenic mice that also showed neurode-
generation but no plaques [15]. During the last years, it has
been convincingly reported in several mouse models
including APPSDLPS1M146L [69], APPSLPS1M146L [70],
Tg2576 [60], 3xTg-AD [48], 5xFAD [47], APPArc [33, 40],
APPT714I mice [63], and in APPSLPS1KIM233T,L235P mice
[10] in which it was recently shown to correlate with
neuron loss [8, 12, 14], as well as in a recently described
mouse model expressing only pyroglutamate modiﬁed Ab
peptides within neurons [67].
Compared to mouse tissue, human tissue is more vari-
able and factors like post-mortem delay, agonal state, and
uneven tissue ﬁxation, often of a prolonged duration, can
interfere with immunohistochemical results. Although pH-
dependent heat pretreatment is commonly used to reliably
retrieve masked antigens from formalin-ﬁxed, parafﬁn-
embedded postmortem brain [41, 42, 58], most of the
staining protocols for intracellular Ab applied so far show
considerable variation in use, duration and concentration of
heat and formic acid (FA) treatment. Microwave heat
pretreatment enhances the immunoreactive signal of in-
traneuronal Ab as compared to conditions in which no or
enzymatic pretreatment was applied [18]. FA is widely
used to increase the staining of plaque pathology in AD;
yet, the effect of FA on intraneuronal Ab staining has been
reported to be low and similar to the effect of heat [20], or
even to counteract the enhancing effect of heat pretreat-
ment on intraneuronal Ab immunohistochemical detection
[49]. On the other hand, formic acid pretreatment has been
successfully used to improve aggregated a-synuclein
staining in Lewy bodies and dystrophic neurites [61].
The present study optimized the staining protocol for
intraneuronal Ab using a highly speciﬁc N-terminal Ab
antibody on human AD tissue after testing various pre-
treatment conditions of heat and/or FA. The optimized
protocol was then used to screen a series of sporadic AD
cases and non-demented controls for the intensity of in-
traneuronal Ab staining, which was then analyzed in a
correlation analysis with patient data including ApoE
genotype. A signiﬁcant correlation between intraneuronal
Ab accumulation and the presence of at least one ApoE4
allele was established.
Materials and methods
AD brain tissue
Parafﬁn-embedded blocks from cortex and hippocampus of
AD (n = 20) and control patients (n = 10) were acquired
from the Netherlands Brain Bank (NBB, Amsterdam, The
Netherlands) [51] that works with a rapid autopsy program
and aims to keep postmortem delay (PMD) to a minimum.
The NBB abides to all local ethical legislation, and per-
mission was obtained for all brain autopsies and for the use
of the tissues and clinical data for research purposes.
To minimize variation as much as possible, control sub-
jects were matched to the AD cases for age, sex,
ﬁxation time, pH of the cerebrospinal ﬂuid, and PMD.
Tissue of all subjects was investigated by a team of trained
neuropathologists using a range of conventional and
neuropathological stainings. The presence or absence of
neuropathological changes was conﬁrmed in the hippo-
campus and a range of other brain regions including the
frontal and temporal cortex and the cerebellum. None of
the control subjects had suffered from any primary neu-
rological or psychiatric disease or brain metastases nor did
they have a history of drug treatment or medication.
At autopsy, the hippocampus was dissected and ﬁxed in
0.1 mol/L phosphate-buffered 4% formaldehyde (Sigma,
St. Louis, MO, USA) solution (pH 7.2) for a period of
approximately 4–5 weeks. Tissue was then dehydrated in
graded ethanol and embedded in parafﬁn. 4-lm-thick tissue
sections were cut for all patients from the midlevel of the
hippocampus on a Leica microtome and mounted on
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123SuperFrost Plus slides (Menzel-Gla ¨ser, Braunschweig,
Germany). The following data were available for each
patient: diagnosis, gender, age, post-mortem delay, disease
duration, pH CSF, Braak stage, ApoE genotype, brain
weight, as well as the medical history. In addition, infor-
mation on extracellular plaque load was provided which
contains a semi-quantitative score based on silver and 6F/3D
(DAKO, Denmark, 1:400) immunostainings ranging from
O (very few) to C (heavy plaque load) (Table 1).
The APOE genotyping of all patients was done
according to standard protocols [66]. In brief, frozen
human cortical samples were physically homogenized and
powdered. DNA was then extracted and puriﬁed using
standard methodology. Subsequently, parts of the APOE
gene were ampliﬁed by means of PCR before the ampliﬁed
DNA was fragmented using the restriction enzyme CfoI
that is single nucleotide polymorphism (SNP) sensitive.
Fragment size was then evaluated from their mobility in
PolyNat gel system stained with SYBR-Green [31].
Immunohistochemistry on formalin-ﬁxed,
parafﬁn-embedded sections
Immunohistochemistry was performed as described previ-
ously [70]. In brief, sections were deparafﬁnized in xylene
and rehydrated in a series of ethanol. After treatment with
0.3% H2O2 in PBS to block endogenous peroxidases, either
no further treatment was applied or antigen retrieval was
performed by boiling sections for 10 min in a microwave
oven in 0.01 M citrate buffer pH 6.0 and/or incubating
sections for 3 min in 88% FA. After long-term ﬁxation,
various antigens can be masked by formalin crosslinks
Table 1 Clinicopathological data of the human brain material
Diagnosis Gender Age (years) PMD (h:min) Brain weight (g) Braak stage ApoE Plaque load Intraneuronal Ab
AD F 88 05:25 1,109 IV e4/e3C ???
AD M 91 04:10 1,160 IV e4/e2C ???
AD F 92 03:50 1,043 IV e4/e2C ???
AD M 81 04:50 1,253 IV ND C ???
Control M 78 18:00 1,222 I e4/e3C ???
Control F 90 07:15 1,047 I e2/e2B ???
AD F 91 03:45 1,011 IV e4/e3C ??
AD F 84 10:00 1,206 IV e4/e3B ??
AD F 79 05:20 1,213 IV e4/e3B ??
AD F 91 04:15 1,202 IV e4/e3B ??
AD F 86 03:45 1,098 IV e4/e3C ??
AD M 92 03:30 1,175 IV e3/e3C ??
AD F 88 03:30 1,002 IV e3/e3C ??
AD F 88 12:15 935 IV e3/e3C ??
AD F 86 04:10 1,083 IV e3/e3B ??
Control M 70 07:45 1,560 0 e4/e3B ??
Control M 73 24:45 1,267 0 e3/e3O ??
AD F 87 02:55 928 IV e4/e3C ?
AD M 93 05:50 1,220 IV e3/e3C ?
AD F 92 05:10 1,110 IV e3/e3C ?
AD F 93 06:15 943 IV e3/e3C ?
AD F 84 04:15 1,023 IV e3/e2B ?
AD F 85 02:45 1,247 IV e2/e2C ?
Control M 84 09:00 1,367 I e3/e3O ?
Control F 78 04:50 1,250 I e3/e3A ?
Control F 82 11:30 1,159 I e3/e3O ?
Control M 70 07:30 1,280 0 e3/e2O ?
AD M 86 06:00 1,377 IV e3/e3B -
Control M 91 \39:20 1,185 I e3/e3O -
Control F 88 03:45 1,195 I e3/e3O -
Listed are diagnosis, sex, age, post-mortem delay (PMD, h:min), brain weight (g), Braak stage, ApoE genotype (combination of alleles 2, 3, and
4), extracellular plaque load, and intraneuronal Ab1-x staining intensity
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123which hamper immunocytochemical detection. For many
antigens, this can be overcome by heat-induced antigen
retrieval [42, 57, 62]. Non-speciﬁc binding sites were
blocked by treatment with 4% skim milk and 10% fetal calf
serum in PBS, prior to addition of the primary antibodies.
Primary antibodies used were directed against N-terminal
Ab peptides [Ab[N], IBL (rabbit polyclonal, catalog
No. 18584), Hamburg, Germany, 1:200] [35], G2-10
(Ab40, The Genetics Company, Switzerland, 1:500),
ﬁbrillar Ab oligomers (OC, generous gift of C. Glabe and
R. Kayed 1:200) [32], Ab17–24 (4G8, Covance, 1:1,000),
APP C-terminal (Synaptic Systems, Germany, 1:500) and
glial ﬁbrillary acidic protein (GFAP, Synaptic Systems,
Germany, 1:1,000). All primary antibodies were incubated
overnight in a humid chamber at room temperature. Single
staining was visualized using the ABC method with Vec-
tastain Kit (Vector Laboratories, Burlingame, USA) and
0.5 mg/mL DAB as chromogen providing a reddish brown
color (10 min exposure for human tissue). In order to rule
out a cross-reactivity of Ab[N] with APP C-terminal
fragments, SPA4CT mice overexpressing the b-cleaved
APP C-terminal fragment under the control of the prion
protein promoter [52], were stained with Ab[N] and a
C-terminal APP antibody (Supplementary Fig. 1).
Intraneuronal Ab intensity was rated in the hippocampal
region based on Ab[N] staining intensity in CA4, CA3, and
CA1 corresponding to either: no staining in any of the
regions: 0 (-); weak staining in CA4 and CA3, but nothing
in CA1: 1 (?); moderate staining in CA4 and CA3, but
nothing or little in CA1: 2 (??); intense staining in all
three regions: 3 (???) (Fig. 4a–l).
Double immunocytochemical staining was visualized
using the ABC method with DAB together with the His-
toGreen kit (Linaris, Germany) providing a blue color.
Counterstaining was carried out with hematoxylin.
Statistical analysis
Kolmogorov–Smirnov test was applied to examine which
variables showed signiﬁcant deviations from normal dis-
tribution. Most of the parameters, especially intraneuronal
Ab, showed signiﬁcant deviation from normal distribution,
and thus non-parametric tests were performed in the
following analyses. Spearman rank correlations were cal-
culated between intraneuronal Ab and age, brain weight,
extracellular plaque load, and post-mortem delay. Non-
parametric Mann–Whitney U test was performed between
intraneuronal Ab and the factors gender, diagnosis, and
number of ApoE 4 alleles. Non-parametric Kruskal–Wallis
tests were computed between intraneuronal Ab and Braak
stage, where subgroup analysis between two groups was
performed with Mann–Whitney U tests. As the study is
explorative, the P values are given without Bonferroni
adjustments. A binary logistic regression with dependent
variable number of ApoE 4 alleles (0, C1) and independent
variables intraneuronal Ab, diagnosis, gender, age, and
Braak stage was computed with the enter method, includ-
ing all speciﬁed independent variables in the model. That
way, the analysis on a correlation between intraneuronal
Aß and ApoE 4 alleles was controlled for the indicated
variables.
Results
Effect of formic acid and heat on staining
of intraneuronal Ab in AD patients
Optimization for intraneuronal Ab staining was performed
in hippocampal parafﬁn sections of sporadic AD cases
using the Ab N-terminal antibody detecting Ab peptides
starting with an aspartate at position 1. This antibody has
been previously reported not to cross-react with full-length
APP or b-C-terminal fragments [13, 35]. In addition, no
cross-reactivity to APP C-terminal fragments could be
demonstrated by staining SPA4CT mice overexpressing the
b-cleaved APP C-terminal fragment C99. While strong
immunoreactivity using a C-terminal APP antibody could
be demonstrated in dentate gyrus granule cells and axonal
ﬁber tracts like the corpus callosum, staining with the
Ab[N] antibody was consistently negative (Supplementary
Fig. 1). Even without any antigen retrieval, a faint fairly
homogenous intraneuronal Ab1-x staining could be detec-
ted (Fig. 1a). Yet, 10-min heat treatment in 0.01 M citric
acid buffer pH 6 dramatically increased the intraneuronal
Ab1-x staining showing a granular staining pattern and
concentration around the nucleus (Fig. 1b). Compared to
no pretreatment, 3-min FA pretreatment did not improve
the staining of intracellular Ab1-x (Fig. 1c), and actually
very clearly counteracted the enhancing effect of the heat
pretreatment on intraneuronal Ab1-x staining (Fig. 1d). In
addition to the fairly homogenous and punctate staining in
the cytoplasm, some nuclei were observed to be surrounded
by a highly granular Ab staining pattern and were present
in all three AD cases, and with all applied protocols
(Fig. 1c). Double labeling for Ab1-x and astrocytes using
the Ab[N] antibody visualized by DAB and the GFAP
antibody visualized by Histogreen revealed that this highly
abundant granular staining pattern in CA4 and CA3 of the
hippocampal formation of many sporadic AD cases to be
astrocytes accumulating Ab (Fig. 2a, b, black arrows). In a
few cases, astrocytes with no granular Ab accumulation
could be found in close proximity to neurons (Fig. 2c, d).
The presence of intraneuronal Ab in the hippocampal
region of sporadic AD cases was conﬁrmed qualitatively by
staining using the OC antibody recognizing Ab ﬁbrils and
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traneuronal staining much like that of Ab[N] with heat
pretreatment alone (Fig. 3a, b) as well as with combined
heat and 3-min FA pretreatment. The latter was actually
slightly more intense than that enhanced by heat alone
(Fig. 3c, d).
The widely used 4G8 antibody was applied to further
conﬁrm the presence of intraneuronal Ab using heat pre-
treatment and was found to produce a prominent and
intense granular staining. This pattern differed from that
detected by OC or Ab[N] antibodies (Fig. 3e, f), with the
granules being much larger and surrounding the nucleus in
a cap-like manner.
Intraneuronal Ab staining in sporadic AD and control
patients
Hippocampal sections from 10 controls and 20 sporadic
AD patients were stained with the Ab[N] antibody, and
their intraneuronal Ab1-x intensity was analyzed based on
evaluation of the staining intensity in CA4, CA3, and CA1
(Fig. 4a–l). Four AD patients and two controls were found
to accumulate the highest degree of intraneuronal Ab1-x
peptides, whereas nine AD patients and two controls
accumulated a moderate amount of these Ab peptides. Six
AD patients and four controls accumulated low amount of
Ab peptides, whereas only one AD and two control patients
were devoid of accumulation of Ab1-x peptides (Table 1).
By non-parametric statistical analysis, the accumulation of
intraneuronal Ab1-x was found to show no correlation with
age, brain weight, post-mortem delay, gender, diagnosis, or
Braak stage; however, a correlation between intraneuronal
Ab1-x accumulation and extracellular plaque load was
established (P = 0.0138, r = 0.4446). Surprisingly, the
ApoE genotype was found to strongly correlate with the
presence of intraneuronal Ab, where having one ApoE4
allele strongly correlated with increased intraneuronal
Ab1-x staining (Table 2; P = 0.002), which was also
signiﬁcant after Bonferroni adjustment (P = 0.023). Fur-
thermore, from binary logistic regression with dependent
variable ApoE 4 alleles and independent variables intran-
euronal Ab, diagnosis, gender, age, and Braak stage, there
was only a signiﬁcant inﬂuence of ApoE 4 alleles on
intraneuronal Ab (Wald statistic = 5.85; P = 0.016; odds-
ratio = 16.38; 95% conﬁdence interval = [1.70; 157.9]),
while there was no signiﬁcant inﬂuence of the other
Fig. 1 Optimization for intraneuronal Ab1-x staining in the hippo-
campal formation of sporadic AD cases using the Ab[N] antibody in
parafﬁn-embedded sections. A faint homogenous intraneuronal Ab1-x
staining could be detected even without any antigen retrieval (a).
However, 10-min heat pretreatment in citric acid buffer pH 6
dramatically increased the intraneuronal Ab1-x staining that at higher
magniﬁcation showed granularity and concentration around the
nucleus (b). Compared to no treatment, 3-min formic acid (FA)
pretreatment failed to improve intraneuronal Ab1-x staining (c). In
the combined treatment of heat and FA, FA actually counteracted the
enhancing effect of the heat pretreatment (d). Besides the intraneu-
ronal Ab1-x staining, smaller nuclei surrounded by a highly granular
Ab staining pattern were observed with all the protocols
(c, arrowheads). Scale bar 50 lm
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The rate of correct classiﬁcations for ApoE 4 alleles
increased from 62 to 79% after the independent variables
were entered to the model.
To conﬁrm the results of the Ab[N] staining in the
detection of intraneuronal Ab peptides in human post-
mortem tissue, the same cohort of patients was stained
using the commercially available antibody G2-10, which
recognizes a neo-epitope at the C-terminus of Ab40
peptides (Supplementary Fig. 2). A correlation analysis
between the staining pattern of the two antibodies revealed
a highly signiﬁcant correlation (P = 0.002; r = 0.55),
corroborating the validity of the staining protocol.
Discussion
The effect of heat and FA pretreatment was semi-quan-
titatively investigated in human AD tissue using a highly
speciﬁc N-terminal-speciﬁc antibody detecting Ab1-x.I t
has been previously reported that this antibody speciﬁ-
cally recognizes Ab peptides, without cross-reaction to
APP or APP C-terminal fragments [13, 35]. The optimi-
zation was performed in parafﬁn-embedded hippocampal
sections from sporadic AD cases by means of combina-
tions of acid and heat pretreatments, essential conditions
for antigen retrieval from brain tissue ﬁxed for prolonged
periods of time [42, 57, 62]. As the Ab[N] antibody is
directed against the aspartate at position 1 of Ab,i tm i g h t
also detect APP C-terminal fragments bearing the same
epitope. To overcome this problem, we stained tissue
sections from a transgenic mouse model overexpressing
the b-cleaved APP C-terminal fragment C99 (SPA4CT
mice) [52], and found no evidence for any cross-reactivity
to b-CTF in formalin-ﬁxed and parafﬁn-embedded
material. However, residual cross-reactivity using other
techniques cannot be completely ruled out. Some in-
traneuronal Ab1-x staining was evident even without any
pretreatment, but heat dramatically increased the intran-
euronal staining of smaller granules throughout the
cytoplasm concentrating around the nucleus in all inves-
tigated hippocampal regions, especially in the CA4
region. In contrast, FA pretreatment did not increase the
staining of intraneuronal Ab1-x as compared to sections
Fig. 2 Double labeling of
Ab1-x in reddish brown (DAB)
using Ab[N] antibody and
astrocytes in blue (Histogreen,
black arrowheads) using a
GFAP antibody in parafﬁn-
embedded sections. The highly
granular staining pattern
surrounding the smaller nuclei
was due to astrocytes
accumulating Ab and was found
in CA4 (a) as well as in CA3 (b)
of many sporadic AD cases.
However, in some AD cases,
astrocytes without granular
staining were found close to
neurons in both CA4 (c) and
CA3 (d). Scale bar 33 lm
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reduced the enhancing effect of heat; the combination of
heat and FA only slightly increased the staining of Ab1-x
as compared to no pretreatment (Fig. 1d, h, l), resulting in
much less retrieval than heat alone. The counteracting
effect of FA on the heat-induced staining of intraneuronal
Ab1-x peptides corroborates ﬁndings of another study
using an Ab42(43) speciﬁc antibody (BC-05) and an
autoclave heating protocol that reported a counteracting
effect of FA on heat-induced Ab42 staining [49]a n di si n
line with previous studies showing that FA preferentially
retrieves nuclear rather than cytoplasmic antigens [7, 57,
62]. Taken together, the strong improvement in intran-
euronal Ab immunoreactive signal after this pretreatment
Fig. 3 Intraneuronal staining
detected by OC and 4G8
antibodies in a sporadic AD
brain. The OC antibody
disclosed intraneuronal Ab
staining much like that of
Ab[N] with both 10-min heat
pretreatment alone (a, b) and
combined heat and 3-min
formic acid (FA) treatment
(c, d). With 10-min heat
pretreatment, the 4G8 antibody
produced a different, highly
abundant and granular
intracellular staining (e, f).
Bottom left corners of a, c, and e
show intracellular staining at a
high magniﬁcation. Scale bar
50 lm
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123may explain discrepancies with older literature, where
antigen retrieval was generally not applied.
These ﬁndings are in contrast to the observations in
mouse models, where FA clearly enhanced staining of in-
traneuronal Ab peptides with heat yielding no, or only a
minor increase [13]. The difference in the effect of heat and
FA between mouse and human tissue could be explained
by differences in the Ab species that accumulate in the
cells. In the AD mouse models, much of the intraneuronal
Ab induced by FA pretreatment seemed to be aggregated
peptides. Possibly, the intraneuronal Ab1-x in AD tissue
could reﬂect soluble oligomeric species that may be
enhanced by heat but counteracted by FA pretreatment. In
agreement, low-n oligomeric Ab have been detected inside
primary human neurons [64].
The presence of intraneuronal Ab in sporadic AD tissue
was further supported by staining with the polyclonal OC
antibody recognizing ﬁbrillar Ab oligomers and Ab ﬁbrils
[32]. An intense intraneuronal Ab staining was observed
after heat pretreatment as well as with additional FA pre-
treatment that enhanced intraneuronal OC staining. This is
in contrast to the deleterious effects of FA pretreatment on
the detection of Ab1-x, but agrees with the suggestion that
FA enhances the staining of aggregated Ab ﬁbrils recog-
nized by the OC antibody. The staining retrieved by heat
pretreatment could thus be due to detection of oligomeric
Fig. 4 Rating of intraneuronal
Ab1-x staining intensity. ???
was assigned to cases with very
strong intraneuronal Ab staining
in CA4, CA3, as well as in CA1
(a–c). ?? was assigned to cases
with weaker but still obvious
intracellular Ab staining in CA4
and CA3 and low staining in
CA1 (d–f). ? was assigned to
cases with a very faint
intracellular Ab staining in CA4
and CA3 and apparently no
staining in CA1 (g–i). 0 was
assigned to cases showing no
intracellular Ab staining either
in CA4, CA3, or CA1 (j–l).
Scale bar 50 lm
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previous studies suggesting that Ab oligomerization starts
within neurons [59, 64].
It is known that besides Ab peptides starting with an
aspartate at position 1, a variety of different N-terminal
truncated Ab peptides have been identiﬁed in AD brain
tissue [28, 53]. Especially compact Ab deposits in human
brain often contain pronounced N-terminal degradation and
post-translational modiﬁcations [36]. While N-terminal
modiﬁcations of Ab have been identiﬁed to occur within
neurons [8], it is likely that the majority of intraneuronal
Ab peptides start with the aspartic acid at position 1 as
cleavage by BACE is the initial step for Ab generation.
Intraneuronal Ab originates exclusively from intraneu-
ronal sources. Whether it can, in addition, be internalized
from external sources is not yet clariﬁed. Yet, much evi-
dence supports the possibility of a reuptake of Ab peptides
into cells by endocytosis, and members of the lipoprotein
receptor (LDLR) family [9], a7 nicotinic receptors [46], as
well as scavenger receptor for advanced glycation end
products (RAGE) [21, 56, 71] have all been reported to
interact with Ab and to be capable of internalization of
extracellular Ab peptides. In particular, RAGE-Ab com-
plexes have been shown to be internalized and co-localize
with the lysosomal pathway in astrocytes in AD brains
[56]. This is supported by our observation of astrocytes
accumulating high amounts of Ab granules.
The LDLR-related protein (LRP) is a member of the
LDLR family and functions as an ApoE receptor. LRP has
been shown to facilitate rapid endocytosis of APP pro-
moting APP processing and thus Ab generation. In addition
to the effect on APP trafﬁcking, LRP-induced rapid
endocytosis also facilitates cellular uptake of Ab peptides
from the extracellular space, either directly through bind-
ing to Ab or indirectly through interaction with ligands
such as ApoE [9]. Accordingly, knock out of APOE in
PDAPP transgenic mice reduced the accumulation of
intracellular Ab [72]. Given this possible role for ApoE in
the intraneuronal Ab accumulation, we correlated the
intensity of the intraneuronal Ab1-x staining in the hip-
pocampal regions of 20 AD patients and 10 controls to
ApoE genotype and found a highly signiﬁcant correlation
between having one ApoE4 allele and the intensity of
Ab1-x staining (P = 0.002). This is an interesting ﬁnding
as ApoE4 plays an important role in neurodegeneration in
general and in AD in particular (reviewed in [43]). The e4
allele of the ApoE gene is the major known genetic risk
factor for AD with a frequency of *15% in general pop-
ulations but[50% in AD patients [16]. Moreover, ApoE4
inﬂuences beta-amyloid degradation [73] brain and neu-
ronal activity [39, 55] while senile plaques are more
frequent in ApoE4-carriers compared to non-carriers. This
was most evident during the age of 50–59 years, with
*41% of e4-carriers bearing senile plaques, compared to
only *8% in non-carriers [34]. This suggests that there is a
differential development of AD-associated changes in the
brain of individuals having at least one e4 allele, which
starts already in middle age.
Crossing PDAPP mice with mice in which the endoge-
nous mouse ApoE was substituted with human ApoE2,
ApoE3 or ApoE4 resulted in a substantial and early
increase in brain Ab42 levels, prior to extracellular plaque
deposition [5]. In addition, intraneuronal Ab accumulation
Table 2 Spearman correlation between intraneuronal Ab and the
dichotomic dependent variables sex, diagnosis, and the factor ApoE4
alleles by non-parametric Mann–Whitney U tests
Intraneuronal Abeta
Gender
Male
N 11
M 1.64
SD 1.12
Female
N 19
M 1.68
SD 0.82
Z -0.1
df 1
P 0.95
Diagnosis
Control
N 10
M 1.40
SD 1.08
AD
N 20
M 1.80
SD 0.83
Z -1.1
df 1
P 0.31
ApoE4
No ApoE4 alleles
N 18
M 1.22
SD 0.81
1 ApoE4 allele
N 11
M 2.27
SD 0.65
Z -3.1
df 1
P 0.002
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123has been previously linked to ApoE. PDAPP mice
overexpressing mLRP2 had higher hippocampal detergent-
soluble Ab42 levels than PDAPP wildtype mice. Further-
more, cortical intraneuronal Ab42 was signiﬁcantly
reduced in PDAPP mice lacking ApoE, leading to the
assumption that ApoE facilitates intraneuronal Ab accu-
mulation [72].
ApoE4-transgenic mice housed in an enriched environ-
ment showed increased levels of oligomerization and
deposition of Ab peptides in hippocampal neurons com-
pared to ApoE3-transgenic mice housed under the same
conditions[38].Furthermore,inhibitionoftheAb-degrading
enzyme neprilysin in ApoE3 and ApoE4 mice results in an
ApoE4 isoform-speciﬁc degeneration of hippocampal CA1
neurons, which is accompanied by intracellular accumu-
lation of Ab and ApoE and lysosomal activation [6]. In
good agreement with this lysosomal pathology, altered
endocytic pathway activity is one of the earliest known
intraneuronal changes occurring in sporadic AD, and it has
been shown that the ApoE4 genotype promotes early-stage
endocytic pathway activation [11]. In conclusion, having
optimized techniques for reliable detection of intraneuronal
Ab, our subsequent analysis revealed a strong association
between the ApoE4 genotype and the presence of intran-
euronal Ab. These results conﬁrm recent data obtained in
experimental settings and are consistent with an important
role for intracellular Ab metabolism, possibly mediated
through ApoE4, in AD etiology.
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